Non-small cell squamous lung carcinoma

This early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…

This phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…

This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …

This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…

This study tests whether adding a targeted chemoembolization procedure to standard immunotherapy can help people with stage IV lung squamous cell carcinoma live longer without their cancer growing. About 166 participants who have already responded to initial treatment will be ran…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recr…

This phase 2 trial tests whether the drug zipalertinib, given together with standard chemotherapy, can shrink tumors in people with a specific genetic type of non-small cell lung cancer before they have surgery. The study plans to enroll 16 adults with stage II to IIIB disease wh…

This Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had p…

This study tests whether adding an experimental drug called HLX07 to standard immunotherapy and chemotherapy helps people with advanced squamous non-small cell lung cancer. About 720 adults with stage 3B/4 disease will receive either the new combo or a placebo with standard treat…